Holen Sie sich die Stockscreener-App
0.2925
3.53%
-0.0107
Handel nachbörslich:
.29
-0.0025
-0.85%
Schlusskurs vom Vortag:
$0.3032
Offen:
$0.308
24-Stunden-Volumen:
3.50M
Relative Volume:
1.28
Marktkapitalisierung:
$3.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.53M
KGV:
-0.0607
EPS:
-4.82
Netto-Cashflow:
$-11.12M
1W Leistung:
+22.03%
1M Leistung:
+27.51%
6M Leistung:
-74.69%
1J Leistung:
-81.49%
1-Tages-Spanne:
$0.29
$0.3227
1-Wochen-Bereich:
$0.24
$0.3448
52-Wochen-Spanne:
$0.15
$3.10
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
7380 COCA COLA DRIVE, HANOVER
Vergleichen Sie PCSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.2925 | 2.85M | 0 | -11.53M | -11.12M | -4.82 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Processa Pharmaceuticals (PCSA) Highlights Cancer Drug Advances at ASCO 2025 | PCSA Stock News - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting | PCSA Stock News - GuruFocus
Processa Pharmaceuticals presents cancer drug advances at ASCO - Investing.com Australia
Processa Pharmaceuticals Highlights Next Generation Cancer Therapies with Three Accepted Abstracts at 2025 ASCO Annual Meeting - Nasdaq
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting - GlobeNewswire
Latest Clinical Trial Data: Processa Presents 3 Cancer Treatment Breakthroughs at ASCO 2025 - Stock Titan
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.5% – What’s Next? - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - MSN
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 - Barchart.com
There is no way Processa Pharmaceuticals Inc (PCSA) can keep these numbers up - Sete News
Processa Pharmaceuticals (PCSA) Expected to Announce Earnings on Friday - Defense World
Processa Pharmaceuticals Inc: Rising -91.68% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Taking a Closer Look At Processa Pharmaceuticals Inc (PCSA) Following Its Recent Trade - knoxdaily.com
Processa Pharmaceuticals Inc [PCSA] Shares Rise 8.43 % on Wednesday - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa Pharmaceuticals Inc (PCSA) can make a big difference with a little luck - Sete News
A Closer Look at Processa Pharmaceuticals Inc (PCSA) Stock Gains - investchronicle.com
Recent Insider Activity Suggests Potential Gains for Processa Pharmaceuticals Inc (PCSA) - knoxdaily.com
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 - GlobeNewswire
FDA Project Optimus: Processa Unveils New Approach for Rare Disease Treatment Success - Stock Titan
Data-Based Insights About Processa Pharmaceuticals Inc (PCSA) - stocksregister.com
Processa Pharmaceuticals stock hits 52-week low at $0.22 - Investing.com
PCSA Stock Sees Decline of Approximately -11.67% in Last Five Days - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday - Defense World
Processa Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Processa Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Thursday - Defense World
Processa Pharmaceuticals Inc. (PCSA) reports earnings - qz.com
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference - The Manila Times
Cancer Therapy Innovator Processa Pharmaceuticals Opens Door to Investors at Elite MedInvest Conference - StockTitan
Processa Pharmaceuticals stock hits 52-week low at $0.43 By Investing.com - Investing.com Australia
Processa Pharmaceuticals stock hits 52-week low at $0.43 - Investing.com India
Ulcerated Necrobiosis Lipoidica Market to Expand Significantly by 2034, States DelveInsight Reports | Processa Pharmaceuticals - Barchart
Processa Pharmaceuticals stock hits 52-week low at $0.46 - Investing.com
Processa Pharma Stock Price, Quotes and Forecasts - Benzinga
The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl
Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Processa Pharmaceuticals faces Nasdaq delisting risk over share price By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation - Defense World
Processa Pharmaceuticals IncOn Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance - Marketscreener.com
Processa Pharmaceuticals Inc (PCSA) Shares Soar Above 1-Year High - The News Heater
Processa Pharmaceuticals to Present at 2025 BIO CEO & Investor Conference - Nasdaq
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Financial Analysis: Processa Pharmaceuticals Inc (PCSA)’s Ratios Unveil Key Insights - The Dwinnex
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):